571 related articles for article (PubMed ID: 15476513)
1. Permanent 125I-seed brachytherapy or radical prostatectomy: a prospective comparison considering oncological and quality of life results.
Borchers H; Kirschner-Hermanns R; Brehmer B; Tietze L; Reineke T; Pinkawa M; Eble MJ; Jakse G
BJU Int; 2004 Oct; 94(6):805-11. PubMed ID: 15476513
[TBL] [Abstract][Full Text] [Related]
2. Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer.
Bradley EB; Bissonette EA; Theodorescu D
BJU Int; 2004 Nov; 94(7):1003-9. PubMed ID: 15541117
[TBL] [Abstract][Full Text] [Related]
3. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life.
Jo Y; Junichi H; Tomohiro F; Yoshinari I; Masato F
BJU Int; 2005 Jul; 96(1):43-7. PubMed ID: 15963118
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer.
Wyler SF; Engeler DS; Seelentag W; Ries G; Schmid HP
Urol Int; 2009; 82(1):17-23. PubMed ID: 19172091
[TBL] [Abstract][Full Text] [Related]
5. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
6. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
Satoh T; Ishiyama H; Matsumoto K; Tsumura H; Kitano M; Hayakawa K; Ebara S; Nasu Y; Kumon H; Kanazawa S; Miki K; Egawa S; Aoki M; Toya K; Yorozu A; Nagata H; Saito S; Baba S
BJU Int; 2009 Apr; 103(8):1064-8. PubMed ID: 19040526
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
[TBL] [Abstract][Full Text] [Related]
9. Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal study.
Namiki S; Satoh T; Baba S; Ishiyama H; Hayakawa K; Saito S; Arai Y
Urology; 2006 Dec; 68(6):1230-6. PubMed ID: 17141839
[TBL] [Abstract][Full Text] [Related]
10. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
Stone NN; Stock RG
Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
[TBL] [Abstract][Full Text] [Related]
11. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
[TBL] [Abstract][Full Text] [Related]
12. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy.
Miller DC; Sanda MG; Dunn RL; Montie JE; Pimentel H; Sandler HM; McLaughlin WP; Wei JT
J Clin Oncol; 2005 Apr; 23(12):2772-80. PubMed ID: 15837992
[TBL] [Abstract][Full Text] [Related]
14. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
Aaronson DS; Yamasaki I; Gottschalk A; Speight J; Hsu IC; Pickett B; Roach M; Shinohara K
BJU Int; 2009 Sep; 104(5):600-4. PubMed ID: 19245439
[TBL] [Abstract][Full Text] [Related]
15. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
Lehrer S; Cesaretti J; Stone NN; Stock RG
BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
[TBL] [Abstract][Full Text] [Related]
16. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?
Boorjian SA; Bianco FJ; Scardino PT; Eastham JA
BJU Int; 2005 Oct; 96(6):773-6. PubMed ID: 16153197
[TBL] [Abstract][Full Text] [Related]
17. Permanent prostate brachytherapy for Japanese men: results from initial 100 patients with prostate cancer.
Okaneya T; Nishizawa S; Nakayama T; Kamigaito T; Hashida I; Hosaka N
Int J Urol; 2007 Jul; 14(7):602-6. PubMed ID: 17645602
[TBL] [Abstract][Full Text] [Related]
18. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
[TBL] [Abstract][Full Text] [Related]
19. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice.
Sharkey J; Cantor A; Solc Z; Huff W; Chovnick SD; Behar RJ; Perez R; Otheguy J; Rabinowitz R
Brachytherapy; 2005; 4(1):34-44. PubMed ID: 15737905
[TBL] [Abstract][Full Text] [Related]
20. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
